| Date Filed | Type | Description |
| 10/04/2023 |
4
| HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Sold 2,500 shares
@ $15.77, valued at
$39.4k
|
|
| 10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
4
| HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Sold 2,500 shares
@ $18.92, valued at
$47.3k
|
|
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
4
| HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Exercised 460 options to buy
@ $12, valued at
$5.5k
|
|
| 06/12/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 10.4% stake in RAPT THERAPEUTICS INC |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/25/2023 |
4
| Robbins Wendye (Director) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Granted 12,940 options to buy
@ $20.93, valued at
$270.8k
|
|
| 05/25/2023 |
4
| RIEFLIN WILLIAM JL (Director) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Granted 12,940 options to buy
@ $20.93, valued at
$270.8k
|
|
| 05/25/2023 |
4
| Lyons-Williams Lori (Director) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Granted 12,940 options to buy
@ $20.93, valued at
$270.8k
|
|
| 05/25/2023 |
4
| Kozick Linda (Director) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Granted 12,940 options to buy
@ $20.93, valued at
$270.8k
|
|
| 05/25/2023 |
4
| GRAY MARY ANN (Director) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Granted 12,940 options to buy
@ $20.93, valued at
$270.8k
|
|
| 05/25/2023 |
4
| Giordano Michael F (Director) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Granted 12,940 options to buy
@ $20.93, valued at
$270.8k
|
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"RAPT Therapeutics Reports First Quarter 2023 Financial Results Company maintains strong cash position of $231.6 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2023. “In 2023, we are continuing to focus on advancing our two lead programs, RPT193 and FLX475,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “In the first quarter, we expanded our RPT193 program with the initiation of a Phase 2a clinical trial in asthma. We co..." |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/14/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results Company maintains strong cash position of $249.1 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “This progress has positioned us ...",
"29 8 15 43" |
|
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
4
| HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Sold 5,000 shares
@ $29.62, valued at
$148.1k
|
|
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/06/2023 |
4
| HO WILLIAM (Chief Medical Officer) has filed a Form 4 on RAPT Therapeutics, Inc.|
Txns:
| Exercised 460 options to buy
@ $12, valued at
$5.5k
|
|
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 5.3% stake in RAPT Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 9.9% stake in RAPT THERAPEUTICS INC |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/10/2023 |
SC 13G/A
| FMR LLC reports a 11.6% stake in RAPT THERAPEUTICS INC |
|